europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio Advanced Therapy

28/02/2019
POSITION PAPER
EuropaBio Advanced Therapy

Advanced Therapies Transforming Medicine

What are Advanced Therapy Medicinal Products?
Advanced therapies offer patients new hope against a range of devastating illnesses, such as inherited diseases, leukaemia, blindness, Parkinson’s disease, epilepsy and many others.

Advanced Therapy Medicinal Products are a new generation of innovative medicines based on genes, cells or tissues. Advanced therapies have ground-breaking therapeutic potential, particularly in disease areas where treatment options are absent or inadequate. Excitingly, these therapies are starting to allow us to cure challenging conditions with a one-off treatment. As a result, they also have transformative implications for families, society and healthcare systems.

EuropaBio invites EU decision-makers to engage with us and our healthcare biotech members who are leading the field in advanced therapies.

Download the file below to read the full Factsheet.

EuropaBio Advanced Therapy


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
01/02/2023

Joint Statement: The Data Act is a leap into the unknown


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies